GeneFab

Alameda, CA and South San Francisco
Claimed Profile Cell Therapies Autologous therapies Allogeneic therapies Stem cell therapies Gene-Modified Cell Therapy Lentiviral gamma-retroviral
Program data pending ClinicalTrials.gov matching · Last scored 2026-07-06
61.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: GeneFab

Signal Score
61.5/100 (as of 2026-07-06)
Quality Compliance
Assessment pending
Headquarters
Alameda, CA and South San Francisco
Founded
2023
Max Bioreactor Scale
200L
Website
Modalities
Cell Therapies, Autologous therapies, Allogeneic therapies, Stem cell therapies, Gene-Modified Cell Therapy, Lentiviral, gamma-retroviral
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About GeneFab

Examples of our GMP manufacturing support and strategic partnerships: GeneFab conducts the clinical manufacturing of Senti Bio’s chimeric antigen receptor natural killer (CAR-NK) medicines pipeline, SENTI-202. https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-closing-transaction-leveraging-its-cmc; and Patnership with RegCell to advance their regulatory T cell (Treg) therapies for autoimmune diseases, https://www.outsourcedpharma.com/doc/genefab-regcell-announce-partnership-advance-autoimmune-cell-therapy-clinical-trials-0001

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCell Therapies, Autologous therapies, Allogeneic therapies, Stem cell therapies, Gene-Modified Cell Therapy, Lentiviral, gamma-retroviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 63.0
Broad modality coverage (7 modalities)
Sites: Alameda, CA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
StatusAvailable
Broad modality coverage (7 modalities)
Sites: Alameda, CA
Broad modality coverage (7 modalities)

Frequently Asked Questions About GeneFab

What is GeneFab's CDMO Signal Score?
GeneFab has a Signal Score of 62/100, based on quality, operations, financial stability, and capacity data.
Evaluating GeneFab for a manufacturing program?
Use the free AI matchmaker to compare GeneFab against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Gene-Modified Cell Therapy CDMOs → Lentiviral CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
August Bioservices
San Carlos, CA
Signal Score: 77.4
AAV, Lentiviral
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 73.4
mRNA, Gene Therapy, Cell Therapy, Lentiviral
VIVEbiotech
San Sebastián, Spain
Lentiviral